Latest Research Shows Sex at the Wrong Time is Primary Cause for Failure to Conceive Wednesday 11 July 2007 PDF Print Issue Date: 11th July 2007 Latest Research Shows Sex at the Wrong Time is Primary Cause for Failure to Conceive New research, published in ‘Current Medical Research & Opinion’ shows that a small, hand-held, digital diagnostic device that identifies the fertile days of a woman’s cycle and allows couples to time intercourse accordingly, should be considered before other attempts at infertility diagnosis are made*1. In a retrospective, observational study of 196 women who successfully conceived using the Clearblue Fertility Monitor, previous history data showed that: • 126 women had consulted a medical professional for advice • 81 had been prescribed medication, including clomiphene citrate (helps stimulate ovulation) and gonadotrophins (FSH and LH Hormones) • Many of the women had also had tests or treatments including; - vaginal ultrasound scans - hormonal blood tests - intrauterine insemination - laparoscopy - analysis of their partners’ semen - in-vitro fertilisation. After switching to the Clearblue Fertility Monitor 91.9% conceived within three cycles, indicating that the probable cause of their previous failure to conceive was, in fact, the incorrect timing of intercourse. This research also highlights the issue of unnecessary early medical intervention and suggests that the Clearblue Fertility Monitor can help to reduce both the financial and emotional costs of evaluations and treatments for couples trying to conceive. * Unless there are conflicting clinical reasons As most conceptions occur following intercourse during the six days leading up to and ending on the day of ovulation, the Clearblue Fertility Monitor is designed to identify the days on which sexual intercourse is most likely to lead to conception, thereby maximising a woman’s chance of conceiving. It goes a step further than traditional ovulation kits, by detecting two hormones that help identify the ‘High’ fertility days leading up to ovulation and the ‘Peak’ fertility days when ovulation takes place. Dr Jayne Ellis for Clearblue says: “This research further proves that the Clearblue Fertility Monitor is the most advanced home method of maximising a woman’s chances of conceiving. The personal information it provides can empower women who are planning a pregnancy because it enables them to understand their own individual cycle, which varies from woman to woman, and it identifies their wider ‘window of fertility’ because it detects both ‘High’ and ‘Peak’ fertility days.” The research findings are published in a paper entitled: MISTIMING OF INTERCOURSE AS A PRIMARY CAUSE OF FAILURE TO CONCEIVE: RESULTS OF A SURVEY ON USE OF A HOME-USE FERTILITY MONITOR”, Current Medical Research and Opinion. Vol. 23, (2) 2007, Pages 301-306 (request the complete paper from Lisa Penney on 01628 526208). For more information on the Clearblue Fertility Monitor visit www.Clearblue.info/uk - Ends - Reference: 1. “Mistiming of intercourse as a primary cause of failure to conceive: results of a survey on use of a home-use fertility monitor”. Current Medical Research and Opinion. Vol. 23, No.2, 2007, 301-306. About the Clearblue Fertility Monitor The Monitor measures two hormones to identify your ‘High’ and ‘Peak’ fertility days – oestrogen and Luteinising Hormone (LH). When oestrogen reaches a critical level it causes a rapid rise in the level of LH – the LH surge – which in turn causes the release of an egg from an ovary. This is ovulation and it occurs approximately 24-36 hours after the LH surge. The Clearblue Fertility Monitor is 99% accurate in detecting the LH surge in laboratory tests. The Clearblue Fertility Monitor is easy to use; tells you when to test your urine (you will be asked to do 10 or 20 tests per cycle, depending on your cycle length and variability) and stores your information for a number of cycles, building a unique picture for you. The Clearblue Fertility Monitor is available from Boots, larger pharmacies and online at www.Clearblue.info/uk, price £99.99 (RRP) and Test Sticks, which are sold in packs of 20 have an RRP of £19.90 per pack. Further information and user support is available at www.Clearblue.info/uk or phone the Careline on: 0845 607 6596 (charged at local rate) or IRL: 1890 882 884 (charged at local rate). The Careline is open from 7am to 3pm Monday to Friday, excluding Bank Holidays. Key features and benefits * 99% accurate in detecting the LH surge in laboratory tests * Proven to help women conceive - Increases the chances of conception by 89% within two cycles of use* * Detects 2 hormones, which means it more accurately identifies more fertile days than other fertility monitors * Identifies a broader window for conception (not just the 2 most fertile days that an ovulation test will identify) * The Monitor tells the user when to test * Clearly shows daily fertility status – interprets results for the user * Proactive approach – actionable information in advance of ovulation * Monitors hormones directly, compared to other methods e.g. testing temperature, mucus or saliva, all of which can be affected by external factors e.g. illness and stress * Technology simplified – a clear digital display giving the user key information * Builds up a detailed knowledge of a woman’s own unique cycle * Works with a woman’s body naturally and it’s not invasive * Within first 2 cycles of use, based on a study of 302 women who used the Clearblue Fertility Monitor for 2 cycles compared to a control group of 347 women who did not use the Clearblue Fertility Monitor. Increased pregnancy rate with the use of the Clearblue Easy Fertility Monitor. Fertility & Sterility, February 2007, Vol 87(2). Pages 329-334 About Unipath The Clearblue Fertility Monitor is a Unipath product. Unipath, with its head office in Bedford UK, produces a comprehensive range of women’s health diagnostic products. Unipath also produces a range of dedicated high quality, rapid, professional diagnostic tests, under the Clearview brand, which are used by GPs and nurses across the country. Unipath is a division of Inverness Medical Innovations of Waltham, Massachusetts and employs more than 500 people in the UK, with additional offices in the US, Sweden and Germany. Its products are sold in more than 80 countries worldwide. Further information about Unipath is available at www.unipath.com For further press information contact Lisa Penney or Victoria Newlands on 01628 526208 or email email@example.com or firstname.lastname@example.org This press release was distributed by ResponseSource Press Release Wire on behalf of Nobull Communications in the following categories: Children & Teenagers, Health, Women's Interest & Beauty, Medical & Pharmaceutical, for more information visit http://pressreleasewire.responsesource.com/about.